**Study Overview:** This study is for adults with a type of lung cancer called Non-Squamous Non-Small Cell Lung Cancer (NSCLC), which has already been treated before. The goal is to test an investigational drug named *telisotuzumab vedotin*. An investigational drug means it is not yet approved for general use. Participants will receive this drug through an IV (intravenous) drip, which goes directly into the bloodstream. Out of about 150 people, each will be placed into one of three groups, chosen randomly. These groups will receive different amounts of the drug. The study will last for 3 years. During this time, participants will need to visit the hospital or clinic regularly for medical check-ups, blood tests, and to answer questions about how they feel. - **Duration & Visits:** The study lasts for 3 years with regular hospital or clinic visits. - **Treatment:** Participants receive an investigational drug, *telisotuzumab vedotin*, through an IV. - **Potential Risks:** There might be more treatment burden compared to standard care.